Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.
Andrea Eleazar, MHS
Andrea Eleazar, MHS, is an assistant editor for Targeted Oncology, with interests in noncommunicable diseases, health equity research, and global health. Eleazar holds a Master of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, as well as a BS in Public Health and certificate in Writing & Publishing from Drexel University.
Articles by Andrea Eleazar, MHS
A study reveals that obesity and sex significantly influence liver recurrence and survival rates in pancreatic cancer patients post-surgery.
New research highlights narsoplimab's potential to significantly reduce mortality in high-risk patients with thrombotic microangiopathy after stem cell transplants.
Results of a recent study reveal significant racial differences in renal cell carcinoma histology and outcomes, highlighting the need for ancestry-informed kidney care strategies.
Revumenib gains FDA approval for treating relapsed mNPM1 AML, showcasing promising efficacy and safety data from the AUGMENT-101 trial.
The FDA fast tracks MT-125, a promising new treatment for glioblastoma, enhancing patient care and expediting drug development.
New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.
The FDA fast-tracks pamlectabart tismanitin, a promising treatment for relapsed multiple myeloma, enhancing its development and review process.
New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.
Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.
FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.
The FDA reviews XS003, a new nilotinib formulation for CML, promising improved safety and convenience for patients.
A groundbreaking study reveals the effectiveness of dabrafenib and trametinib in treating advanced thyroid cancer, showcasing significant survival benefits.
Combination therapy of percutaneous hepatic perfusion with immune checkpoint inhibitors shows promising survival rates in metastatic uveal melanoma patients.
New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.
Early-stage cervical cancer treatment significantly boosts survival rates in older patients, highlighting the need for tailored care strategies.
Sacituzumab tirumotecan significantly improves progression-free survival in HR+/HER2– breast cancer compared with traditional chemotherapy.
Durvalumab combined with FLOT chemotherapy significantly enhances overall survival in resectable gastric adenocarcinoma, establishing a new standard of care.
A new study reveals serplulimab significantly improves event-free survival in gastric cancer, offering a promising alternative to traditional chemotherapy.
FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data and innovative technology.
Medicaid expansion significantly improves long-term cancer survival rates, especially for vulnerable populations, highlighting the need for broader adoption across states.
The FDA fast-tracks NG-350A, an innovative immunotherapy for advanced rectal cancer, aiming to enhance treatment options and patient outcomes.
The FDA designates ficerafusp alfa as a breakthrough therapy for treating HPV-negative head and neck cancer, enhancing patient outcomes and options.
New findings reveal that combining niraparib with abiraterone significantly extends progression-free survival in patients with HRR-altered metastatic prostate cancer.
A study reveals significant disparities in access to CAR T therapy for multiple myeloma among racial and ethnic minorities, despite similar treatment outcomes.
FDA fast tracks ADCE-D01, a promising treatment for soft tissue sarcoma, aiming to expedite patient access and improve survival rates.
Innovative NBTXR3 shows promise in enhancing radiotherapy for recurrent head and neck cancer, potentially transforming treatment options for patients.
New findings from the SUNMO study highlight the promising efficacy and safety of Mosun-Pola for treating relapsed large B-cell lymphoma, offering a chemotherapy-free option.
The FDA has approved cemiplimab as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma.
Atebimetinib combined with modified gemcitabine/nab-paclitaxel shows remarkable survival rates in first-line pancreatic cancer, surpassing standard treatments.